Adaptive Biotechnologies (ADPT) announced that Palmetto GBA, a Medicare Administrative Contractor, MAC, that assesses diagnostic technologies through its Molecular Diagnostics Services Program, MoIDX, has expanded coverage of clonoSEQ to include detection and monitoring of measurable residual disease, MRD, in Medicare patients with mantle cell lymphoma
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT: